ArticleVirology journal2025
Study on immunogenicity of recombinant ferritin hemagglutinin of canine distemper virus.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- mRNA-LNP vaccine encoding CDV hemagglutinin confers effective protection in raccoon dogs.NPJ vaccines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCanine distemper virus (CDV) hemagglutinin protein (H), as one of the surface glycoproteins of the virus, helps attach the virus to the host cell through its interaction with cell receptors, makes hemagglutinin protein a key target for the development of neutralizing antibodies.
methodsIn this study, H protein sequences were analyzed by conservation analysis and prediction of multiple immune cell epitopes, three possible epitope sequences were identified. The epitopes were ligated to Ferritin vector with linkers to construct pET30a-Ferritin-Hemagglutinin-Canine distemper virus (FHCDV). pET30a-FHCDV was transfected into E.coli BL21, the expressed protein was extracted by nickel column affinity chromatography and dialysis concentration. Evaluate vaccine efficacy through nasal mucosal and muscular administration.
resultsThe best expression conditions of FHCDV in E. coli transfected with pET30a-FHCDV were 25 °C and 1 mM Isopropyl β-D-1-Thiogalactopyranoside (IPTG). The results of Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis(SDS-PAGE) and Non-denaturing Polyacrylamide Gel Electrophoresis (Native-PAGE)showed that the purity of purified FHCDV was about 95% and had capable of self-assembly. The results of Dynamic Light Scattering (DLS) and Transmission Electron Microscope (TEM) characterization showed the recombinant protein FHCDV self-assembly into tetrameric caged nanoparticles with a diameter of 16.56 nm. Significant secreted IgA (sIgA) was generated in BALB/C female mice with nasal mucosal immunization. The titers of sIgA antibodies against FHCDV in nasal wash and bronchoalveolar lavage fluid were about 1865 ng/ml and 3943 ng/ml. FHCDV was used as an intramuscular vaccination to inject BALB/C female mice with aluminium adjuvant (Al), Oligodeoxynucleotide (CpG), and polyethyleneimine (PEI) respectively. All immunization groups produced distinct antibodies against the antigenic epitopes of FHCDV. The antibody titer of FHCDV group was 1.28 × 10
conclusionsThese results indicate that self-assembled multi-epitope FHCDV nano vaccines elicit effective immune responses with a favorable safety profile, providing a promising strategy for canine distemper virus vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.